Evidence map›Paper›PMID 34504959›Full record

ArticleClinical and translational radiation oncology2021

Impact of pretreatment second look

Olgun Elicin, Bernd Vollnberg, Mohamed Shelan, Elena Riggenbach, Beat Bojaxhiu, Etienne Mathier, Roland Giger, Daniel M Aebersold, Bernd Klaeser

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational radiation oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Olgun ElicinDepartment of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Bernd VollnbergDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Mohamed ShelanDepartment of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Elena RiggenbachDepartment of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Beat BojaxhiuDepartment of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Etienne MathierDepartment of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Roland GigerDepartment of Otorhinolaryngology, Head and Neck Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Daniel M AebersoldDepartment of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Bernd KlaeserDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
University of Bern · CHUniversity Hospital of Bern · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients diagnosed with locoregionally advanced head and neck squamous cell carcinoma (LAHNSCC) regularly undergo staging with

methodsConsequent treatment changes were categorized as minor and major. Minor changes were defined as PET/CT-based modifications of RT plans, e.g., the addition of anatomical compartments, changes in high- and low-risk dose levels or both. Major changes included changes from curative to palliative treatment intent and alterations of interdisciplinary treatment plans, such as the addition of induction chemotherapy, switch to primary surgery, no treatment and/or the necessity of additional diagnostic work-up resulting in the postponement or cancellation of treatment.

resultsThirty-two newly diagnosed LAHNSCC patients who were treated between 2014 and 2018 underwent second-look PET/CT (median interval 42.5 days). Second-look PET/CT led to locoregional and distant upstaging in 3/32 and 1/32 patients, respectively. In 1/32 patients (3%), second-look PET/CT led to a palliative approach with systemic treatment. New lymph node metastases were discovered in 16 patients, 6 of whom also showed significant progression of the primary tumor, resulting in minor changes in 16 of the remaining 31 patients (52%) who were treated curatively.

conclusionIf RT treatment planning of LAHNSCC was delayed by more than 4 weeks after initial PET/CT staging or when progression was clinically suspected, a second look at

Indexed as

Head and neck cancerPositron emission tomographyRadiotherapySquamous cell carcinomaStaging

Identifiers

PMID34504959
PMCPMC8414040
OpenAlexW3197582642

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.